Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.70160 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Tara Lazetic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hearing Loss, Cisplatin, Stria Vascularis. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted. Growing evidence suggests certain genetic variants expressed in the SV are significant risk factors for ototoxicity, which may be leveraged to better understand cisplatin‐induced hearing loss. Also highlighted are innovative developments in integrating genomic and transcriptomic data through multi‐omic approaches that may be translated to improve future genetic testing and otoprotectant development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
- The Children's Hospital Foundation of Manitoba, Winnipeg, Manitoba, Canada.
- CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.
- Centre of Aging, University of Manitoba, Winnipeg, Manitoba, Canada.
- Biological Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.
ORCID-Profile: Tara Lazetic, Deanne Nixie R Miao, Britt I Drögemöller, Alain Dabdoub, Julia M Abitbol
Zitieren
APA
Lazetic, T., Miao, D. N. R., Drögemöller, B. I., Dabdoub, A., & Abitbol, J. M. (2025). Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70160
Vancouver
Lazetic T, Miao DNR, Drögemöller BI, Dabdoub A, Abitbol JM. Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70160
BibTeX
@article{Lazetic2025,
author = {Lazetic, Tara and Miao, Deanne Nixie R and Drögemöller, Britt I and Dabdoub, Alain and Abitbol, Julia M},
title = {Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.70160}
}
EUVIMED